{"url_path":"/sec/cik-0001106838/10-k/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-K/A","doc_date":"2026-07-17","source_url":"https://www.sec.gov/Archives/edgar/data/1106838/0001493152-26-033712-index.html","accession_number":"0001493152-26-033712","cik":"0001106838","ticker":null,"issuer_name":"Sonnet BioTherapeutics Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1106838/0001493152-26-033712-index.html","primary_entity_key":"0001106838","primary_entity_name":"Sonnet BioTherapeutics Holdings, Inc."},"word_count":728,"has_tables":true,"body_markdown":"true\nFY\n0001106838\n\n0001106838\n\n2024-10-01\n2025-09-30\n\n0001106838\n\n2025-03-31\n\n0001106838\n\n2025-12-12\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\nxbrli:pure\n\niso4217:EUR\n\nSONN:Segment\n\n \n\n \n\n** **\n\n**UNITED\nSTATES**\n\n**SECURITIES\nAND EXCHANGE COMMISSION**\n\n**WASHINGTON,\nD.C. 20549**\n\n \n\n \n\n \n\n**FORM\n10-K/A**\n\n**(Amendment\nNo. 1) **\n\n \n\n \n\n \n\n**(Mark\nOne)**\n\n** **\n\n☒\n**ANNUAL\nREPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For\nthe fiscal year ended September 30, 2025**\n\n \n\n**OR**\n\n** **\n\n☐\n**TRANSITION\nREPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For\nthe transition period from              to**\n\n \n\n**Commission\nfile number: 001-35570**\n\n** **\n\n \n\n****\n\n \n\n**SONNET\nBIOTHERAPEUTICS HOLDINGS, INC.**\n\n**(Exact\nname of registrant as specified in its charter)**\n\n** **\n\n \n\n****\n\n \n\n**Delaware**\n \n**20-2932652**\n\n**(State\nor other jurisdiction of**\n\n**incorporation\nor organization)**\n\n \n\n**(I.R.S.\nEmployer**\n\n**Identification\nNo.)**\n\n \n\n**100\nOverlook Center, Suite 102**\n \n \n\n**Princeton,\nNJ**\n \n**08540**\n\n**(Address\nof principal executive offices)**\n \n**(Zip\nCode)**\n\n \n\n**Registrant’s\ntelephone number, including area code: (609) 375-2227**\n\n \n\n**Securities\nregistered pursuant to Section 12(b) of the Act: None**\n\n  \n\n**Securities\nregistered pursuant to Section 12(g) of the Act: None**\n\n \n\nIndicate\nby check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.\n\nYes\n☐ No ☒\n\n \n\nIndicate\nby check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒\n\n \n\nIndicate\nby check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange\nAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)\nhas been subject to such filing requirements for the past 90 days. Yes ☒ No ☐\n\n \n\nIndicate\nby check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule\n405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant\nwas required to submit such files). Yes ☒ No ☐\n\n \n\nIndicate\nby check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting\ncompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”\n“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge\naccelerated filer\n☐\nAccelerated\nfiler\n☐\n\nNon-accelerated\nfiler\n☒\nSmaller\nreporting company\n☒\n\n \n \nEmerging\ngrowth company\n☐\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate\nby check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness\nof its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered\npublic accounting firm that prepared or issued its audit report. ☐\n\n \n\nIf\nsecurities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant\nincluded in the filing reflect the correction of an error to previously issued financial statements. ☐\n\n \n\nIndicate\nby check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation\nreceived by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐\n\n \n\nIndicate\nby check mark if the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒\n\n \n\nThe\naggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant was $4,150,174 on March 31, 2025,\nthe last business day of the registrant’s most recently completed second fiscal quarter, based on the closing price of $1.34 on\nthat date.\n\n \n\nIndicate\nthe number of shares outstanding of each of the registrant’s classes of common equity, as of December 12, 2025:\n\n \n\n**Class**\n \n**Number\nof Shares**\n\nCommon\nStock, $0.0001 par value\n \n1\n\n \n\n**Documents\nincorporated by reference**\n\n \n\nNone.\n\n \n\n \n\n \n\n \n\n \n\n** **\n\n**Explanatory\nNote**\n\n** **\n\nSonnet\nBiotherapeutics Holdings, Inc. is filing this Amendment No. 1 to its Annual Report on Form 10-K for the year ended September 30, 2025\nfor purpose of substituting the correct version of the Report of Independent Registered Public Accounting Firm.\n\n \n\nOther\nthan as disclosed above and the dating of this Amendment, there are no changes to that Annual Report.\n\n** **\n\n \n\n \n\n** **\n\n**TABLE\nOF CONTENTS**"}